AMD3465 hexahydrobromide is a potent CXCR4 chemokine receptor antagonist. It is primarily used in research settings to study the role of the CXCR4 receptor in various biological processes, particularly in cancer and stem cell mobilization. By blocking CXCR4, it inhibits the interaction between CXCR4 and its ligand, CXCL12, which plays a key role in tumor metastasis, cell migration, and homing of hematopoietic stem cells. In oncology research, AMD3465 hexahydrobromide has been investigated for its potential to suppress the spread of cancer cells, especially in breast cancer and leukemia, where CXCR4 overexpression is linked to poor prognosis. It is also explored for enhancing stem cell mobilization from bone marrow into peripheral blood, which can improve the efficiency of stem cell collection for transplantation. Additionally, due to its ability to cross the blood-brain barrier, it shows utility in studying neuroinflammatory conditions and central nervous system involvement in diseases like HIV and certain cancers. Its small molecular size and high selectivity make it a valuable tool in preclinical studies aimed at developing new therapeutic strategies targeting the CXCR4 signaling pathway.